LAUSR

INTRODUCTION The Pfizer-BioNTech COVID-19 vaccine was first approved for use in December 2020. Studies have shown the vaccine to be highly effective at preventing transmission of SARS-CoV-2 and reducing the severity of COVID-19. Reported side effects of the vaccine include injection-site pain, mild-to-moderate fatigue, mild-to-moderate headache, and, more rarely, anaphylaxis and nonanaphylactic allergic reactions. Here, we describe a severe nonanaphylactic allergic reaction to the Pfizer-BioNTech COVID-19 vaccine in a patient with no significant history of atopy.